NCT06629207 Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder
| NCT ID | NCT06629207 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-10-07 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-10-07 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The study will use artificial intelligence to analyze imaging and develop a reliable method to predict and stratify patients approaching conversion to overt a-synucleinopathy. Participants will be clinically evaluated and 2 imaging procedures will be done.
Eligibility Criteria
Inclusion Criteria: 1. Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders 2. Written informed consent Exclusion Criteria: 1. Known diagnosis of PD or other neurodegenerative disorder 2. Unequivocal signs of parkinsonism on examination 3. Narcolepsy or other known causes of RBD 4. Moderate to severe obstructive sleep apnea 5. Abnormal neurological or MRI examination
Contact & Investigator
Kuanggyu Shi, Prof. Dr. ing.
PRINCIPAL INVESTIGATOR
University Bern, Inselspital, Center for Artificial Intelligence in Medicine
Frequently Asked Questions
Who can join the NCT06629207 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06629207 currently recruiting?
Yes, NCT06629207 is actively recruiting participants. Contact the research team at axel.rominger@insel.ch for enrollment information.
Where is the NCT06629207 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT06629207 clinical trial?
NCT06629207 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Kuanggyu Shi, Prof. Dr. ing. at University Bern, Inselspital, Center for Artificial Intelligence in Medicine. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.